SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-20-254645
Filing Date
2020-09-25
Accepted
2020-09-25 16:37:59
Documents
1
Group Members
VERSANT VANTAGE I GP, L.P.VERSANT VANTAGE I GP-GP, LLCVERSANT VANTAGE I, L.P.VERSANT VENTURES VI GP, L.P.VERSANT VENTURES VI GP-GP, LLCVERSANT VOYAGEURS I GP COVERSANT VOYAGEURS I GP, L.P.VERSANT VOYAGEURS I PARALLEL, L.P.VERSANT VOYAGEURS I, L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d74910dsc13da.htm SC 13D/A 188925
  Complete submission text file 0001193125-20-254645.txt   190917
Mailing Address ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO CA 94104
Business Address ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO CA 94104 (415) 801-8100
Versant Venture Capital VI, L.P. (Filed by) CIK: 0001687880 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 139 MAIN STREET CAMBRIDGE MA 02142
Business Address 139 MAIN STREET CAMBRIDGE MA 02142 617-417-5868
Black Diamond Therapeutics, Inc. (Subject) CIK: 0001701541 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91312 | Film No.: 201200595
SIC: 2836 Biological Products, (No Diagnostic Substances)